Table 3 Clinical characteristics of... | American Society of Hematology

Table 3

Clinical characteristics of CTEPH patients with fibrinogen variants

Patient ID	Fibrinogen variant	Age, y/sex	History*	Severity†	Duration of symptoms	PVR, dyn•s/cm⁵		Plasma fibrinogen, mg/dL
Patient ID	Fibrinogen variant	Age, y/sex	History*	Severity†	Duration of symptoms	Preop	Postop	Clauss	Antigen
1	San Diego I	23/M	No	Severe	7 y	311	157	94	96
2	San Diego II	45/F	No	Moderate	9 mo	1175	378	319	317
3	San Diego III	54/F	Yes	Mild	18 mo	1570	172	260	244
4	San Diego IV	49/M	Yes	Mild	20 mo	679	166	NA	NA
5	San Diego V	33/F	No	Moderate	8 mo	772	242	367	451

Patient ID	Fibrinogen variant	Age, y/sex	History*	Severity†	Duration of symptoms	PVR, dyn•s/cm⁵		Plasma fibrinogen, mg/dL
Patient ID	Fibrinogen variant	Age, y/sex	History*	Severity†	Duration of symptoms	Preop	Postop	Clauss	Antigen
1	San Diego I	23/M	No	Severe	7 y	311	157	94	96
2	San Diego II	45/F	No	Moderate	9 mo	1175	378	319	317
3	San Diego III	54/F	Yes	Mild	18 mo	1570	172	260	244
4	San Diego IV	49/M	Yes	Mild	20 mo	679	166	NA	NA
5	San Diego V	33/F	No	Moderate	8 mo	772	242	367	451

PVR indicates pulmonary vascular resistance; and NA, not available.

Family history of acute thrombosis.

Severity of initial acute PE: severe indicates unstable in ICU; moderate, hospitalized; and mild, outpatient.